عنوان
پدید آورنده
موضوع
رده
کتابخانه
محل استقرار
شماره کتابشناسی ملی
شماره
TLpq2516143798
زبان اثر
زبان متن نوشتاري يا گفتاري و مانند آن
انگلیسی
عنوان و نام پديدآور
عنوان اصلي
The Efficacy of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Men and Women with Heart Failure with Reduced Ejection Fraction
نام عام مواد
[Thesis]
نام نخستين پديدآور
Wali, Muhammad Ahmer
نام ساير پديدآوران
Pilote, Louise
وضعیت نشر و پخش و غیره
نام ناشر، پخش کننده و غيره
McGill University (Canada)
تاریخ نشرو بخش و غیره
2020
مشخصات ظاهری
نام خاص و کميت اثر
79
یادداشتهای مربوط به پایان نامه ها
جزئيات پايان نامه و نوع درجه آن
M.Sc.
کسي که مدرک را اعطا کرده
McGill University (Canada)
امتياز متن
2020
یادداشتهای مربوط به خلاصه یا چکیده
متن يادداشت
Background. Angiotensin converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARB) are essential to the treatment of heart failure with reduced ejection fraction (HFrEF). However, little data are available to determine whether their efficacy in reducing hospitalizations and mortality may differ between men and women with HFrEF. Purpose. To explore whether differences exist in the efficacy of ACEi/ARBs in HFrEF by sex. Methods. We conducted a pooled analysis of individual data from 4 randomized clinical trials: The Study of Left Ventricular Dysfunction (SOLVD) Treatment, SOLVD Prevention, Candesartan in Heart Failure: Assessment of Morbidity and Mortality (CHARM) Alternative and Added trials. The primary outcome was a composite of death or hospitalization for heart failure. Multivariable analyses were conducted using Cox proportional hazards models, adjusting for confounders, to obtain sex specific hazard ratios (HRs) and the interaction was tested by a sexby- randomized treatment term. Results. Among the 11,373 participants (19% women; mean age 61.5), women were older, with a higher prevalence of type 2 diabetes and hypertension, and a lower prevalence of ischemic heart disease than men regardless of treatment group. The ACEi/ARBs group had a lower incidence of the primary outcome compared to placebo [13.3 vs 16.6 per 100 person-year], with a similar efficacy in both men and women [adjusted-HR men 0.76 vs women 0.88, p-sex-by-drug interaction = 0.12]. However, women were more likely than men to be hospitalized for HF despite treatment [adjusted-HR men 0.65 95%CI 0.54-0.79 vs women 0.82 95%CI 0.74-0.90, p-sex-by-drug interaction = 0.09]. Conclusions. The association between ACEi/ARB and the primary outcome of death or HF hospitalization did not differ between men and women. However, women were more likely than men to have HF hospitalizations despite ACEi/ARB treatment. Future trials should include a larger enough sample size of women and men to enable sex-specific recommendations about HF drug efficacy.
موضوع (اسم عام یاعبارت اسمی عام)
موضوع مستند نشده
Drug interactions
موضوع مستند نشده
Ejection fraction
موضوع مستند نشده
Epidemiology
موضوع مستند نشده
Gender differences
موضوع مستند نشده
Heart failure
موضوع مستند نشده
Mortality
نام شخص به منزله سر شناسه - (مسئولیت معنوی درجه اول )
مستند نام اشخاص تاييد نشده
Pilote, Louise
مستند نام اشخاص تاييد نشده
Wali, Muhammad Ahmer
دسترسی و محل الکترونیکی
نام الکترونيکي
مطالعه متن کتاب وضعیت انتشار
فرمت انتشار
p
اطلاعات رکورد کتابشناسی
نوع ماده
[Thesis]
کد کاربرگه
276903
اطلاعات دسترسی رکورد
سطح دسترسي
a
تكميل شده
Y
